IVD PRODUCT
ENDO PREDICT®
The second generation of multi-gene for prognostic prediction of breast cancer
Highlights
PREFERRED POPULATION
CLINICAL VALUE
To assess 10-year distant recurrence risk for patients receiving Standard endocrine therapy.
Individualized chemotherapy benefit prediction:
To predict the benefit of chemotherapy combined endocrine therapy in reducing 10-year recurrence risk.
Prolonged endocrinotherapy decision:
For patients without recurrence after 5 years of endocrine therapy only, the risk of distant recurrence in 5-15 years should be detected to provide basis to decide prolonging endocrine therapy
Recommended by authoritative guidelines around the world
